These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 31228946)

  • 1. Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes.
    Lu C; Klement JD; Ibrahim ML; Xiao W; Redd PS; Nayak-Kapoor A; Zhou G; Liu K
    J Immunother Cancer; 2019 Jun; 7(1):157. PubMed ID: 31228946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. G6PD functions as a metabolic checkpoint to regulate granzyme B expression in tumor-specific cytotoxic T lymphocytes.
    Lu C; Yang D; Klement JD; Colson YL; Oberlies NH; Pearce CJ; Colby AH; Grinstaff MW; Ding HF; Shi H; Liu K
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment.
    Katlinski KV; Gui J; Katlinskaya YV; Ortiz A; Chakraborty R; Bhattacharya S; Carbone CJ; Beiting DP; Girondo MA; Peck AR; Puré E; Chatterji P; Rustgi AK; Diehl JA; Koumenis C; Rui H; Fuchs SY
    Cancer Cell; 2017 Feb; 31(2):194-207. PubMed ID: 28196594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans.
    Fujita M; Scheurer ME; Decker SA; McDonald HA; Kohanbash G; Kastenhuber ER; Kato H; Bondy ML; Ohlfest JR; Okada H
    Clin Cancer Res; 2010 Jul; 16(13):3409-19. PubMed ID: 20472682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p50 suppresses cytotoxic T lymphocyte effector function to regulate tumor immune escape and response to immunotherapy.
    Lu C; Klement JD; Smith AD; Yang D; Waller JL; Browning DD; Munn DH; Liu K
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33051343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells.
    Yang H; Yamazaki T; Pietrocola F; Zhou H; Zitvogel L; Ma Y; Kroemer G
    Cancer Res; 2015 Sep; 75(18):3812-22. PubMed ID: 26208907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic T Cells and Granzyme B Associated with Improved Colorectal Cancer Survival in a Prospective Cohort of Older Women.
    Prizment AE; Vierkant RA; Smyrk TC; Tillmans LS; Nelson HH; Lynch CF; Pengo T; Thibodeau SN; Church TR; Cerhan JR; Anderson KE; Limburg PJ
    Cancer Epidemiol Biomarkers Prev; 2017 Apr; 26(4):622-631. PubMed ID: 27979806
    [No Abstract]   [Full Text] [Related]  

  • 8. Type I interferon is selectively required by dendritic cells for immune rejection of tumors.
    Diamond MS; Kinder M; Matsushita H; Mashayekhi M; Dunn GP; Archambault JM; Lee H; Arthur CD; White JM; Kalinke U; Murphy KM; Schreiber RD
    J Exp Med; 2011 Sep; 208(10):1989-2003. PubMed ID: 21930769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD8+ T-cell immunosurveillance constrains lymphoid premetastatic myeloid cell accumulation.
    Zhang W; Zhang C; Li W; Deng J; Herrmann A; Priceman SJ; Liang W; Shen S; Pal SK; Hoon DSB; Yu H
    Eur J Immunol; 2015 Jan; 45(1):71-81. PubMed ID: 25310972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type I Interferon Activates PD-1 Expression through Activation of the STAT1-IRF2 Pathway in Myeloid Cells.
    Liang L; Yang Y; Deng K; Wu Y; Li Y; Bai L; Wang Y; Lu C
    Cells; 2024 Jul; 13(13):. PubMed ID: 38995014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type I Interferon Signaling Is Required for CpG-Oligodesoxynucleotide-Induced Control of
    Schleicher U; Liese J; Justies N; Mischke T; Haeberlein S; Sebald H; Kalinke U; Weiss S; Bogdan C
    Front Immunol; 2018; 9():79. PubMed ID: 29459858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome Proliferator-Activated Receptor δ Suppresses the Cytotoxicity of CD8+ T Cells by Inhibiting RelA DNA-Binding Activity.
    Cen B; Wei J; Wang D; DuBois RN
    Cancer Res Commun; 2024 Oct; 4(10):2673-2684. PubMed ID: 39292167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9-based Knockout Strategy Elucidates Components Essential for Type 1 Interferon Signaling in Human HeLa Cells.
    Urin V; Shemesh M; Schreiber G
    J Mol Biol; 2019 Aug; 431(17):3324-3338. PubMed ID: 31207241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IFNAR1 Deficiency Impairs Immunostimulatory Properties of Neutrophils in Tumor-Draining Lymph Nodes.
    Hussain T; Domnich M; Bordbari S; Pylaeva E; Siakaeva E; Spyra I; Ozel I; Droege F; Squire A; Lienenklaus S; Sutter K; Hasenberg A; Gunzer M; Lang S; Jablonska J
    Front Immunol; 2022; 13():878959. PubMed ID: 35833131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IFN-alpha-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs.
    Hiroishi K; Tüting T; Lotze MT
    J Immunol; 2000 Jan; 164(2):567-72. PubMed ID: 10623796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granzyme B and the downstream granzymes C and/or F are important for cytotoxic lymphocyte functions.
    Revell PA; Grossman WJ; Thomas DA; Cao X; Behl R; Ratner JA; Lu ZH; Ley TJ
    J Immunol; 2005 Feb; 174(4):2124-31. PubMed ID: 15699143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of an IFNAR1 knockout MDBK cell line using CRISPR/Cas9 and its effect on bovine virus replication.
    Geng Y; Jiang C; Yang H; Xia Q; Xu X; Yang K; Yuan X; Chen J; Chen Y; Chen X; Zhang L; Hu C; Guo A
    Front Immunol; 2024; 15():1404649. PubMed ID: 39100665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-time detection of CTL function reveals distinct patterns of caspase activation mediated by Fas versus granzyme B.
    Li J; Figueira SK; Vrazo AC; Binkowski BF; Butler BL; Tabata Y; Filipovich A; Jordan MB; Risma KA
    J Immunol; 2014 Jul; 193(2):519-28. PubMed ID: 24928990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-21 regulates SOCS1 expression in autoreactive CD8
    Sutherland APR; Graham KL; Papadimitriou M; Jhala G; Trivedi P; Catterall T; Fynch S; Kay TWH; Thomas HE
    Sci Rep; 2019 Oct; 9(1):15302. PubMed ID: 31653894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type I IFN protects cancer cells from CD8+ T cell-mediated cytotoxicity after radiation.
    Chen J; Cao Y; Markelc B; Kaeppler J; Vermeer JA; Muschel RJ
    J Clin Invest; 2019 Oct; 129(10):4224-4238. PubMed ID: 31483286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.